Biopharma at the Crossroads

10:30 - 11:25am PST

Virtual

Cell therapy 2.0: The new frontier confronts new safety threats

sponsored by

The first generation of cell therapy developers had to face their own special challenge: cytokine release storm. But now that that hurdle has largely been cleared, the next wave of cell therapies in the clinic are running smack dab into a whole new set of safety issues that have triggered an array of clinical holds in the field. Just what is going wrong here and what can scientists do to get past this threat?

sponsored by

Steve Kanner

Chief Scientific Officer

Caribou Biosciences, Inc.

Rafael Amado

Executive Vice President of R&D and Chief Medical Officer

Allogene Therapeutics

Donna Dambach

Senior Vice President and Head of Development Sciences

Sana Biotechnology

Vijay Reddy Peddareddigari

President, Chief Research & Development Officer

Tmunity Therapeutics

Tamas Oravecz

Chief Scientific Officer

Parthenon Therapeutics

John Carroll

Editor & Founder

Endpoints News

moderator

Joe Codamo

Head of Global Cell Therapy Business

Catalent Cell & Gene

presenting speaker

6:00 - 7:00am PST

Live

Breakfast & Networking

sponsored by

Proof of vaccination required. Mask requirements will follow local mandates.

7:30 - 8:30am PST

Live

Livestream

Managing a biotech in turbulent times

sponsored by

The money tree on Wall Street has withered badly for biotech this year. After a long running boom, generalists are out of here — for now — leaving high risk, high reward plays like biotech high and dry. So it’s time for more careful planning, and that can mean prioritizing the pipeline, looking at cutting the fat without touching the bone and muscle and generally doing a lot better job of managing the burn rate as you steer to a galaxy of catalysts. And we have some of the industry’s top advisors on hand to provide some insights, as well as answer your questions.

sponsored by

Faheem Hasnain

Co-Founder, Chairman, President & CEO

Gossamer Bio

Andrew Lo

Professor, Director of the Laboratory for Financial Engineering

MIT Sloan School of Management

Kristina Burow

Managing Director

Arch Venture Partners

Neil Kumar

Founder, CEO, Director

BridgeBio

Paul Hastings

CEO

Nkarta

Martin Meeson

CEO

FUJIFILM

presenting sponsor

John Carroll

Editor & Founder

Endpoints News

moderator

9:30 - 10:25am PST

Virtual

Decentralized trials

sponsored by

Getting more patients — as well as a more diverse group — to participate in clinical trials has been a hot topic for years now, and some proponents have been urging regulators to modernize how drug developers are allowed to conduct clinical trials. Endpoints News regulatory expert Zachary Brennan will gather a panel of experts together to examine just how this should be done. This is a must-watch panel for anyone interested in drug development.

sponsored by

Ronan Brown

Senior VP and Head of Patient Centric Solutions & Decentralized Trials

IQVIA

Craig Lipset

Advisor and Founder

Clinical Innovation Partners

Bari Kowal

SVP, Development Operations & Portfolio Management

Regeneron

Zachary Brennan

Senior Editor

Endpoints News

moderator

Matt Blume

Vice President, Business Transformation

Catalent Clinical Supply Services

presenting speaker

Senior editor Beth Snyder Bulik is bringing together some of the top execs from biotechs that have made the big leap from development to marketing their own drugs. What does it take to compete with the big established players in pharma? And what are the most common pitfalls in making the transition? If you’re considering a first-time launch – or just curious about how they did it – you won’t want to miss this one.

Vlad Coric

CEO and Chairman of the Board

Biohaven

Rebecca McLeod

US General Manager

Argenx

Max Colao

Chief Commercial Officer

Aurinia Pharmaceuticals

Patricia Torr

President and General Manager

Idorsia Pharmaceuticals US

Beth Snyder Bulik

Senior Editor

Endpoints News

moderator

11:00 - 11:55am PST

Virtual

The future of gene editing

sponsored by

Now that the CRISPR revolution has taken hold, academic scientists and biotechs are expanding the notion of what’s possible with new tools to edit the genome. Bayer, Moderna, Vertex, and other industry leaders have declared the field as a key driver for their future pipelines. We’ll be taking an in-depth look with Metagenomi's CEO and co-founder, Brian C. Thomas, and other thought leaders in the space at how to forge a path for safe and efficacious gene editing therapeutics and the future of enabling technologies that will make this possible. Furthermore, we will focus on the financial and business endeavors that will ultimately make way for breakthroughs in gene editing to benefit patients.

sponsored by

Brian Thomas

CEO and Founder

Metagenomi

Jürgen Eckhardt

Head

Leaps by Bayer

Will Dere

Vice Dean Research

School of Medicine at University of Utah Health Sciences Center

Aude G. Chapuis

Associate Professor, Clinical Research Division / Co-Founder

Fred Hutch Cancer Center / Affini-T Tx

Eric Huang

General Manager and Chief Scientific Officer

Moderna Genomics

John Carroll

Editor & Founder

Endpoints News

moderator